Addressing the unmet need in lung cancer: The potential of immuno-oncology.
Chemotherapy is currently the standard of care for non-oncogene-driven advanced non-small cell lung cancer (NSCLC). Due to improvements in chemotherapeutic choices and supportive care, patients currently typically undergo multiple lines of chemotherapy as their disease progresses. Although treatments have improved over recent years, limited benefits are seen, especially in patients receiving later-line chemotherapy, as response rates can be low, response duration short and survival poor. Furthermore, only a small percentage of patients derive benefit from later-line therapy, with most experiencing deteriorating quality of life and significant toxicities. More recently, molecular targeted therapies have provided improvements in outcomes. However, these treatments only offer a clear benefit in subsets of tumours harbouring the appropriate genomic alteration (mutation, amplification, translocation). Most of the genomic abnormalities susceptible to therapeutic intervention are detected in adenocarcinoma, mainly in never smokers, while alterations in the genome of other histological subtypes are known but specific agents targeting these alterations have yet to be developed. Thus, the therapeutic management of these subtypes represents an ongoing challenge. Recent advances in immunotherapy have highlighted the potential of immuno-oncology based treatments for NSCLC, offering the potential to provide durable responses and outcomes regardless of histology or mutation status. This review discusses the current unmet medical needs in NSCLC, the limits of current first-line and later-line chemotherapy and targeted agents, and the emergence of new therapeutic strategies.
University of Torino, Department of Oncology, Orbassano, Torino, Italy. Electronic address: scagliotti@ihnet.it.
G V
GV
Scagliotti
University of Torino, Department of Oncology, Orbassano, Torino, Italy.
P
P
Bironzo
Respiratory Oncology Unit and Trial Unit, Department of Pulmonology, University Hospitals KU Leuven, Leuven, Belgium.
J F
JF
Vansteenkiste
D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D015415:Biomarkers; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality
D060890:B7-H1 Antigen; D015415:Biomarkers; C423236:CD274 protein, human; D060908:CTLA-4 Antigen
CTLA-4; Immune checkpoint blockade; Immunotherapy; NSCLC; PD-1; PD-L1